EMA endorses global collaboration in vaccine development for coronavirus (COVID-19)

EMA endorses global collaboration in vaccine development for coronavirus (COVID-19)

The European Medicines Agency (EMA) has issued a press release endorsing a joint statement published by the International Coalition of Medicines Regulatory Authorities on the prioritisation of clinical trials to fight coronavirus (COVID-19). The statement was developed with medicines regulators from around the world with the goal of facilitating global collaboration on the development of therapeutics, diagnostics and vaccines against coronavirus. The statement sets out key characteristics of clinical trials that are most likely to generate conclusive evidence needed to accelerate the development of a treatment or vaccine. It also sets out actions that stakeholders involved with coronavirus clinical trials should take to ensure they collect, analyse and report the data required to show that medicinal products will be safe and effective as treatments. Finally, the statement encourages those carrying out clinical trials to make the results of their trials quickly and easily accessible to participants and the public, thereby allowing the global research community to benefit from it.

Read the full statement here.

Source: International regulators provide guiding principles for COVID-19 clinical trials

Related Articles:
Latest Articles: